MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

351.67 +1.98 (+0.56%)
Streaming Delayed Price Updated: 12:21 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 947,570
Open 348.57
Bid (Size) 351.55 (120)
Ask (Size) 351.78 (200)
Prev. Close 349.69
Today's Range 348.57 - 353.25
52wk Range 261.43 - 350.43
Shares Outstanding 538,500,000
Dividend Yield 2.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026
NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while... 
Via MarketMinute
Topics Earnings Economy Government
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering

Performance

YTD
+7.3%
+7.3%
1 Month
+6.7%
+6.7%
3 Month
+20.8%
+20.8%
6 Month
+16.7%
+16.7%
1 Year
+24.3%
+24.3%

More News

Read More
News headline image
Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout ↗
Via Chartmill
News headline image
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
Via MarketMinute
Topics Economy
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?
Via MarketMinute
Topics Economy Supply Chain World Trade
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
2 Dividend Stocks to Buy and Hold For 10 Years ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins
Via Finterra
Topics Economy
News headline image
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks
Via StockStory
Topics Artificial Intelligence
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Via PredictStreet
Topics Economy Intellectual Property
News headline image
1 Healthcare Stock to Keep an Eye On and 2 We Ignore
Via StockStory
Topics Stocks
News headline image
The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26
Via MarketMinute
Topics Artificial Intelligence
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
Via PredictStreet
Topics Earnings Economy Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
Via MarketMinute
Topics Intellectual Property
News headline image
Can These Dividend Stocks Beat the Market Again in 2026? ↗
Via The Motley Fool
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
Via MarketMinute
Topics Economy

Frequently Asked Questions

Is Amgen publicly traded?
Yes, Amgen is publicly traded.
What exchange does Amgen trade on?
Amgen trades on the Nasdaq Stock Market
What is the ticker symbol for Amgen?
The ticker symbol for Amgen is AMGN on the Nasdaq Stock Market
What is the current price of Amgen?
The current price of Amgen is 351.67
When was Amgen last traded?
The last trade of Amgen was at 01/27/26 12:21 PM ET
What is the market capitalization of Amgen?
The market capitalization of Amgen is 189.37B
How many shares of Amgen are outstanding?
Amgen has 189B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story